En DE FR ES PL
Vigantol - instructions for use, reviews, analogs and formulations (drops or oleaginous solution) for the treatment and prevention of vitamin D deficiency in adults, children (including infants and newborns), and during pregnancy. Composition

Vigantol - instructions for use, reviews, analogs and formulations (drops or oleaginous solution) for the treatment and prevention of vitamin D deficiency in adults, children (including infants and newborns), and during pregnancy. Composition

In this article, you can read the instructions for using the drug Wigantol. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Wigantola in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Wigantol in the presence of existing structural analogs.Use for the treatment and prevention of vitamin D deficiency, osteoporosis and rickets in adults, children (including infants and newborns), as well as during pregnancy and lactation. Composition of the preparation.

 

Wigantol - a drug that regulates the exchange of calcium and phosphorus. It replenishes vitamin D3 deficiency. It increases calcium absorption in the intestine and reabsorption of phosphates in the kidneys. Promotes the mineralization of bones and is necessary for the normal functioning of parathyroid glands.

 

Composition

 

Kolekaltsiferol + auxiliary substances.

 

Pharmacokinetics

 

After oral administration, it is absorbed from the distal part of the small intestine. In the blood it binds to alpha2-globulins and partly to albumins. Kolekaltsiferol accumulates in the liver, bones, skeletal muscles, kidneys, adrenals, myocardium, adipose tissue. Penetrates through the placental barrier. Excreted in breast milk. Biotransformation occurs in the liver and kidneys: in the liver, colcalciferol is converted into an inactive metabolite, calcipheidol (25-dihydrocolecalciferol), in the kidneys it is converted from calcipheidol to the active metabolite calcitriol (1,25-dihydroxycolecalciferol) and the inactive metabolite 24,25-dihydroxycolecalciferol. Undergoes intestinal-hepatic recirculation.Excretion occurs mainly with bile and a small amount - kidneys.

 

Indications

  • prevention and treatment of rickets;
  • prevention of vitamin D deficiency in patients from high-risk groups (malabsorption, chronic diseases of the small intestine, biliary cirrhosis, condition after resection of the stomach and / or small intestine);
  • maintenance therapy of osteoporosis (of various origins);
  • osteomalacia (against the background of disorders of mineral metabolism in patients older than 45, prolonged immobilization in case of injuries, compliance with diets with refusal to accept milk and dairy products);
  • treatment of hypoparathyroidism and pseudohypoparathyroidism.

 

Forms of release

 

The solution for oral administration is oily (sometimes mistakenly called drops).

 

Other dosage forms, be it tablets or capsules, do not exist.

 

Instructions for use and dosage

 

The drug is taken orally with milk or other liquid (during meals).

 

Prophylaxis of rickets: full-term healthy children Vigantol is prescribed from 2 weeks of life for 1 drop (about 667 IU of vitamin D3) daily. Premature babies are prescribed from 2 weeks of life 2 drops (1334 ME vitamin D3) daily.The drug should be taken during the first and second years of life, especially in the winter months.

 

Treatment of rickets: appoint 2-8 drops (about 1334-5336 ME vitamin D3) per day. Treatment should be continued for 1 year.

 

Prevention of the risk of diseases associated with vitamin D3 deficiency: 1-2 drops (about 667-1334 IU vitamin D3) per day.

 

Prevention of vitamin D3 deficiency in malabsorption syndrome: 5-8 drops (about 3335-5336 ME vitamin D3) per day.

 

Treatment of osteomalacia caused by vitamin D3 deficiency: 2-8 drops (about 1334-5336 ME vitamin D3) per day. Treatment should be continued for 1 year.

 

Supportive therapy of osteoporosis: 2-5 drops (about 1334-3335 IU of vitamin D3) per day.

 

Treatment of hypoparathyroidism and pseudohypoparathyroidism: depending on the plasma concentration of calcium, 15-30 drops (about 10 005-20 010 IU of vitamin D3) are prescribed per day. The concentration of calcium in the blood should be checked for 4-6 weeks, then every 3-6 months, and adjust the dose according to the calcium content in the blood.

 

Side effect

  • constipation, diarrhea;
  • flatulence;
  • nausea;
  • abdominal pain;
  • diarrhea;
  • decreased appetite;
  • Hypercalcemia and hypercalciuria in case of taking the drug for a long time in high doses;
  • polyuria;
  • myalgia;
  • arthralgia;
  • increased blood pressure;
  • arrhythmias;
  • itching;
  • rash;
  • allergic reactions;
  • hives;
  • headache;
  • impaired renal function;
  • exacerbation of the tuberculous process in the lungs.

 

Contraindications

  • hypercalcemia;
  • hypercalciuria;
  • calcium nefrourolithiasis;
  • thyrotoxicosis (probability of hypersensitivity);
  • renal osteodystrophy with hyperphosphatemia;
  • hypervitaminosis D;
  • hypersensitivity to the components of the drug.

 

Application in pregnancy and lactation

 

Wigantol should be used with caution in pregnancy and during lactation (breastfeeding).

 

During pregnancy and during breastfeeding, adequate intake of vitamin D3 is required.

 

In case of an overdose, hypercalcemia and transplacental penetration of vitamin D3 metabolites into the fetus may occur, which can lead to a teratogenic effect: retardation of mental and physical development of the fetus, specific forms of aortic stenosis.

 

Vitamin D3 and its metabolites are excreted in breast milk.

 

Use in children

 

Use in children (including babies and newborns) is possible according to the indications according to the dosing regimen.

 

special instructions

 

When pseudohypoparathyroidism is necessary to monitor the presence of signs of intoxication. Because at pseudohypoparathyroidism there can be phases of normal sensitivity to vitamin D, it is necessary to correct the dose of the drug. In psevdohypoparathyroidism, which occurred after surgical treatment of the thyroid gland, it is necessary to stop using the drug as the parathyroid glands are restored to prevent intoxication with vitamin D.

 

With caution should prescribe the drug for atherosclerosis, heart failure, kidney failure, sarcoidosis or other granulomatosis, hyperphosphatemia, phosphate nefrourolithiasis (including in the anamnesis), organic heart damage, acute and chronic liver and kidney diseases, gastrointestinal diseases (in tons stomach ulcer and duodenal ulcer), hypothyroidism, pregnancy and breastfeeding, with additional vitamin D3 intake (for example, as part of other drugs).

 

Impact on the ability to drive vehicles and manage mechanisms

 

Studies on the impact on the ability to drive a vehicle and work with mechanisms have not been carried out.

 

Drug Interactions

 

Phenytoin, primidone and barbiturate drugs increase the need for vitamin D3 because of the increased rate of biotransformation.

 

Long-term therapy against the background of simultaneous use of antacids containing ions of aluminum and magnesium, increases their concentration in the blood and the risk of intoxication (especially in the presence of chronic kidney failure).

 

Calcitonin, bisphosphonates (including etidronic, pamidronic acid), plikamycin reduce the effect.

 

Kolestyramin, colestipol, reduce the absorption of fatty-soluble Vitamins from the gastrointestinal tract and require an increase in their dose.

 

Vigantol increases the absorption of phosphorus-containing drugs and the risk of hyperphosphataemia.

 

When used simultaneously with sodium fluoride, the interval between the intake should be at least 2 hours; with oral forms of tetracyclines - not less than 3 hours.

 

With concomitant therapy with glucocorticosteroids (GCS), a decrease in the effectiveness of the drug is possible.

 

Concomitant therapy with cardiac glycosides may increase their toxic potential due to the development of hypercalcemia. In such patients it is necessary to monitor the levels of calcium, ECG,and adjust the dose of cardiac glycosides.

 

Concomitant therapy with benzodiazepine derivatives increases the risk of hypercalcemia.

 

Vitamin D3 can be combined with metabolites or analogues of vitamin D only in exceptional cases and under the control of serum calcium levels.

 

Thiazide diuretics can reduce the excretion of calcium in the urine and, accordingly, increase the risk of hypercalcemia. In such patients, constant monitoring of calcium concentration in the blood should be performed.

 

Rifampicin and Isoniazid may reduce the effect of the drug due to an increased rate of biotransformation.

 

Vigantol does not interact with food.

 

Analogues of the drug Vigantol

 

Structural analogs for the active substance:

  • Aquadetry;
  • Videchol;
  • Vitamin D3;
  • Vitamin D3 is an aqueous solution.

 

Analogues on the curative effect (remedies for the treatment of calcium and rickets metabolism disorders):

  • Additive of calcium;
  • Aquadetry;
  • Alpha D3 Teva;
  • Vidiylin M;
  • Vitrum Prenatal;
  • Hydrocortisone;
  • Kalkohel;
  • Calcevit;
  • Calcemin;
  • Calcemin Advance;
  • Calcium D3 Nycomed;
  • Kaltsinov;
  • Calcium glycerophosphate;
  • Calcium gluconate;
  • Calcium chloride;
  • Materna;
  • Miakaltsik;
  • Osteoka solution;
  • Osteoppan;
  • Tahistin;
  • Fosavans;
  • Fosamax;
  • Celeston;
  • Ergocalciferol;
  • Ethal.

Similar medicines:

Other medicines:

Reviews (0):

Rules for publishing reviews and visitor questions